**Health**
## Parliamentary Group Demands Major Acceleration of Weight-Loss Injection Access on NHS
**London, UK** – A cross-party group of Members of Parliament is calling for a significant increase in the availability of new weight-loss injections, such as Mounjaro (tirzepatide), on the NHS. They have sharply criticised current government plans, which aim to provide the medication to only 6% of eligible patients by 2028, deeming them “unambitious” and insufficient to address the nation’s growing obesity crisis.
In a recent report, the parliamentary group highlighted the transformative potential of these new GLP-1 receptor agonists in tackling obesity, a chronic condition linked to numerous serious health issues including type 2 diabetes, heart disease, stroke, and certain cancers. The MPs argue that the current target — reaching a mere 6% of the clinically eligible population over the next five years — falls far short of what is needed and possible, given the urgency of the public health challenge.
Mounjaro, scientifically known as tirzepatide, belongs to a new class of medications that mimic natural hormones to regulate appetite, reduce food cravings, and improve blood sugar control. Clinical trials have demonstrated significant weight reduction in patients, often exceeding that seen with previous generations of weight-loss drugs. Its dual action on GLP-1 and GIP receptors offers enhanced effectiveness, positioning it as a powerful tool in comprehensive obesity management strategies.
A spokesperson for the parliamentary group stated, “The NHS has a moral imperative to provide effective treatments for chronic conditions. To set such a low bar for access to a truly revolutionary treatment for obesity is a missed opportunity. We must be bolder and more ambitious in leveraging these scientific breakthroughs to improve public health and alleviate pressure on our healthcare system in the long run.”
While acknowledging the substantial cost implications of these advanced pharmaceuticals, the MPs emphasised that inaction on obesity carries an even greater long-term financial burden for the NHS, along with significant human suffering. They advocate for a strategic investment in scaling up the delivery infrastructure, including training more healthcare professionals to prescribe and monitor these treatments, and integrating them effectively into broader weight management programmes.
The call for increased access underscores a broader debate within the UK about how to effectively tackle the escalating obesity crisis. With millions affected, parliamentary scrutiny is pushing the NHS to reconsider its pace and scale of adoption for these transformative medical interventions, aiming to ensure more people can benefit from treatments that promise not just weight loss, but improved overall health and quality of life.
